| 曲普瑞林治疗中国局部晚期或转移性前列腺癌的药物经济学评价 |
| |
| 引用本文： | 唐箫,张田甜,李家豪,刘君,魏田,赵瑾,蒋杰. 曲普瑞林治疗中国局部晚期或转移性前列腺癌的药物经济学评价[J]. 中国医院药学杂志, 2022, 42(16): 1725-1729. DOI: 10.13286/j.1001-5213.2022.16.18 |
| |
| 作者姓名： | 唐箫 张田甜 李家豪 刘君 魏田 赵瑾 蒋杰 |
| |
| 作者单位： | 1. 暨南大学药学院, 广东 广州 510632;2. 益普生(上海)医药科技有限公司市场准入部, 上海 200080;3. 艾昆纬企业管理咨询(上海) 有限公司真实世界研究, 上海 200124;4. 暨南大学东莞研究院;广东 东莞 523808 |
| |
| 摘 要： | 目的：对曲普瑞林治疗局部晚期或转移性前列腺癌（PCa）进行药物经济学评价。方法：从卫生体系角度出发，采用Markov模型，对比曲普瑞林相较于其他促性腺激素释放激素激动剂（luteinizing hormone releasing hormone agonists，LHRHa）的经济性。结果：曲普瑞林3M剂型相较戈舍瑞林和亮丙瑞林3M剂型的增量成本效果比（ICER）分别为41 950元/QALY和6 515元/QALY，均远低于2020年中国的1倍人均GDP。相较于戈舍瑞林和亮丙瑞林3M剂型，曲普瑞林6M剂型为患者增加的QALYs分别为0.14和0.11，同时总成本均降低。结论：与目前已上市的LHRHa相比，曲普瑞林治疗局部晚期或转移性PCa具有成本效果优势。
|
| 关 键 词： | 曲普瑞林 LHRH激动剂 前列腺癌 成本效果 |
| 收稿时间： | 2022-04-04 |
Economic evaluation of triptorelin in the treatment of locally advanced or metastatic prostate cancer in China |
| |
| TANG Xiao,ZHANG Tian-tian,LI Jia-hao,LIU Jun,WEI Tian,ZHAO Jin,JIANG Jie. Economic evaluation of triptorelin in the treatment of locally advanced or metastatic prostate cancer in China[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(16): 1725-1729. DOI: 10.13286/j.1001-5213.2022.16.18 |
| |
| Authors: | TANG Xiao ZHANG Tian-tian LI Jia-hao LIU Jun WEI Tian ZHAO Jin JIANG Jie |
| |
| Affiliation: | 1. School of Pharmacy, Jinan University, Guangdong Guangzhou 510632, China;2. Market Access Department, Ipsen Pharma, Shanghai 200080, China;3. Real World Solution Department, IQVIA, Shanghai 200124, China;4. Dongguan Institute of Jinan University, Guangdong Dongguan 523808, China |
| |
| Abstract: | OBJECTIVE To conduct the economic evaluation of triptorelin in the treatment of locally advanced or metastatic prostate cancer (PCa) in China.METHODS A Markov model was constructed to compare the cost-effectiveness of triptorelin with that of other LHRH agonists from the perdpective of health system.RESULTS The incremental cost-effectiveness ratio (ICER) of triptorelin 3M compared with goserelin 3M or leuprorelin 3M was 41 950 yuan/QALY and 6 515 yuan/QALY, respectively, and both were significantly far lower than the China's per capita GDP in 2020. Compared with goserelin 3M and leuprorelin 3M, triptorelin 6M increased QALYs by 0.14 and 0.11, respectively, while the total cost was reduced.CONCLUSION Compared with currently marketed LHRH agonists, triptorelin is a cost-effective strategy in the treatment of locally advanced or metastatic PCa. |
| |
| Keywords: | triptorelin LHRH agonists prostate cancer cost-effectiveness analysis |
|
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
|
点击此处可从《中国医院药学杂志》下载免费的PDF全文 |
|
